February 2008
Diabetes Health;Feb/Mar2008, Vol. 17 Issue 1, p32
The article presents the views of several readers of "Diabetes Health" on the issue that most diabetes drug trials focus on medication's effect on blood sugar levels, but ignore that medication's impact on other outcomes that are important to patients. One reader asserts that many of the available prescribed diabetes drugs have had side effects and complications associated with them. Another reader shares her experience about the side-effects she had after taking various kinds of drugs for diabetes.


Related Articles

  • Oral antidiabetic agents. Jordan, Sue; Lake, Richard // Nursing Standard;5/18/2005, Vol. 19 Issue 36, p105 

    The article focuses on oral antidiabetic agents, which may be prescribed for people with type 2 diabetes to increase the response to insulin and stimulate the pancreatic output of insulin. The article discusses types of antidiabetic drugs, such as metformin and acarbose, and discusses drug...

  • Pioglitazone benefits outweigh risks.  // Pharmaceutical Technology Europe;Dec2007, Vol. 19 Issue 12, p10 

    The article reports on the confirmation of the positive risk-benefit balance for anti-diabetic drug pioglitazone by the European Medicines Agency (EMEA) in Europe. It is noted that pioglitazone is believed to cause fluid retention and periperal edema and has been associated with upper...

  • Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Irons, Brian K.; Minze, Molly G. // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;2014, Vol. 7, p15 

    Metformin is considered an initial drug of choice for type 2 diabetes mellitus by leading recommendations. When contraindications to its use exist or patients cannot tolerate it due to adverse effects, clinicians have a variety of other classes of agents to treat hyperglycemia associated with...

  • Cancer in a patient receiving IGF-I therapy. Frank, Robert N.; Grunberger, George; Frank, R N; Grunberger, G // Diabetes Care;Mar2000, Vol. 23 Issue 3, p435 

    Comments on the study conducted by Thrailkill, et al, which appeared in the April 1999 issue of `Diabetes Care' about the trial of IGF-I cotherapy in diabetics. Background on the study conducted; Failure of the study to report the occurrence of cancer in a patient related to his participation...

  • Most Diabetes Clinical Trials Ignore Everything But Blood Sugar Control.  // Diabetes Health;Feb/Mar2008, Vol. 17 Issue 1, p32 

    The article focuses on the commentary made by Mayo Clinic physician Victor Montori regarding diabetes drug trials. Statistics show that only one in five trials measures the effect of drugs on quality of life and risk of complications such as death, heart attack and stroke. Montori asserts that...

  • Clinical Trials and Statistical Tribulations. Brian Attig, R.; Clabaugh, Alison // Applied Clinical Trials;Feb2008, Vol. 17 Issue 2, p42 

    The article discusses the clinical trials of Avandia, a diabetes drug introduced by GlaxoSmithKline (GSK). It states that a recent and widely publicized meta-analysis published in the June 14, 2007 issue of the periodical "The New England Journal of Medicine" suggests that the drug is linked to...

  • Innovation! Vaughan, Roger D. // American Journal of Public Health;Aug2008, Vol. 98 Issue 8, p1353 

    The article discusses various reports published within the issue, including one fractional factorial experimental designs and another on the design of more-efficient, longer-term randomized controlled trials and other data management and statistical techniques to help detect adverse drug events...

  • Underrecognition of adverse effects. Kuritzky, Louis // Alternative Medicine Alert;Aug2010 Supplement, p15 

    The article discusses research by M. Zimmerman published in the "Journal of Clinical Psychiatry" which investigated why adverse effects related to medication are usually undetected in clinical trials.

  • Which AEs to collect for supplemental indications?  // Reactions Weekly;12/11/2010, Issue 1331, p3 

    The article discusses research being done on the gathering of adverse event (AE) data in cancer clinical trials, which references a study by L. D. Kaiser and colleagues in the October 4, 2010 issue of the "Journal of Clinical Oncology."

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;5/28/2011, Issue 1353, p2 

    The article reports on the draft guidance released by the Indian Central Drugs Standard Control Organization (CDSCO) in May 2011 geared toward the tightening of requirements for the reporting of serious adverse events occurring during clinical trials.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics